Cidara治疗 CDTX 深 沪
已收盘 11-07 16:00:00 美东时间
104.39
+5.750
+5.83%
华盛通- 最 高105.00
- 今 开98.29
- 成交量 95.51万股
- 最 低 95.87
- 昨 收 98.64
- 总市值 26.47亿
- 52周最高 121.21
- 市盈率 静 --
- 换手率 3.77%
- 52周最低 14.33
- 委 比 -85.07%
- 总股本 2535.81万
- 历史最高 382.60
- 量 比 1.39
- 振 幅 9.26%
- 历史最低 8.00
- 每 手 1
- 风险率 28.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cidara Therapeutics’ Earnings Call Highlights CD388 Progress
Cidara Therapeutics Inc. (($CDTX)) has held its Q3 earnings call. Read on for t...
11-09 08:28
Needham Maintains Buy on Cidara Therapeutics, Raises Price Target to $135
Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and raises the price target from $100 to $135.
11-07 18:12
UPDATE: Cidara Therapeutics Q3 Adj. EPS $(1.43) Misses $(1.35) Estimate
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(1.35) by 6.24 percent. This is a 39.92 percent increase over losses of $(2.38) per share
11-07 06:55
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Baron Health Care Fund buys ABBV, UNH, ROIV; exits WAT and COO
Baron Health Care Fund increased 5.39% in Q3 2025, compared with the 5.05% gain for the Russell 3000 Health Care Index and the 8.18% gain for the Russell 3000 Index. The fund outperformed by 9.30% on ...
10-29 02:19
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
Cidara Therapeutics presented late-breaking data on CD388, a non-vaccine influenza preventative, at the ESWI 10th Influenza Conference. The preclinical studies and Phase 2b NAVIGATE trial demonstrated CD388's effectiveness against multiple influenza strains, with a clear link between drug concentration and efficacy. Cidara aims to advance CD388 into Phase 3 trials to protect vulnerable populations.
10-23 12:00
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Cidara Therapeutics Releases New Phase 2b Clinical Data From Its Navigate Study Showing Its Influenza Preventative Candidate CD388 Demonstrated Up To 76.1% Efficacy Against Influenza A And B In Healthy, Unvaccinated Adults
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it presented late-breaking Phase 2b
10-21 20:10
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
Cidara Therapeutics will present late-breaking Phase 2 clinical data on its antiviral influenza candidate CD388 at ID Week 2025 in Atlanta. The presentation, titled "A Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of CD388," will be held on October 20, 2025, at 3:15 PM ET in session B401-B402. CD388, developed using Cidara's Cloudbreak platform, is designed for universal prevention of seasonal and pandemic influenza wit...
10-13 12:00
